Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers

Abstract

Mass spectrometry-based proteomics is a key player in research efforts to characterize aberrant epigenetic alterations, including histone post-translational modifications and DNA methylation. Data generated by this approach complements and enrich datasets generated by genomic, epigenetic and transcriptomics approaches. These combined datasets can provide much-needed information on various mechanisms responsible for drug resistance, the discovery and validation of potential biomarkers for different diseases, the identification of signaling pathways, and genes and enzymes to be targeted by future therapies. The increasing use of high-resolution, high-accuracy mass spectrometers combined with more refined protein labeling and enrichment procedures enhanced the role of this approach in the investigation of these epigenetic modifications. In this review, we discuss recent MS-based studies, which are contributing to current research efforts to understand certain mechanisms behind drug resistance to therapy. We also discuss how these MS-based analyses are contributing to biomarkers discovery and validation.

Proteomic Insights into Osteoporosis: Unraveling Diagnostic Markers of and Therapeutic Targets for the Metabolic Bone Disease

“…Proteomic data serve as valuable resources for evaluating the efficacy and safety of potential drug candidates in drug development [142,143]. Proteomic data are uniquely valuable for predicting drug responses and discovering biomarkers since drugs primarily interact with proteins in target cells rather than with DNA or RNA [144].…”

Biological Aging Acceleration Due to Environmental Exposures: An Exciting New Direction in Toxicogenomics Research

“…It is much easier to preserve samples (from human subjects or experimental animals or the field) for DNA isolation as opposed to sample preservation for later histone analysis. Moreover, methods for analyzing histone marks like mass spectrometry are also expensive [176].…”